Cargando…
Distinctive phenogroup to differentiate diagnosis of cardiac myxoma vs cardiovascular disease examining blood-based circulating cell biomarkers
Cardiac myxoma (CM) is a potentially life-threatening disease because frequently asymptomatic or debuts with aspecific manifestations. Definitive diagnosis is established by histopathological assessment including tumor and endothelial cell markers. To derive a specific panel of circulating cells ant...
Autores principales: | Donato, Giuseppe, Mignogna, Chiara, Santise, Gianluca, Presta, Ivan, Ferrazzo, Teresa, Garo, Virginia, Maselli, Daniele, Curcio, Antonio, De Rosa, Salvatore, Spaccarotella, Carmen, Mollace, Vincenzo, Gentile, Francesco, Indolfi, Ciro, Malara, Natalia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10663517/ https://www.ncbi.nlm.nih.gov/pubmed/37990043 http://dx.doi.org/10.1038/s41598-023-47639-y |
Ejemplares similares
-
Innate immunity in cardiac myxomas and its pathological and clinical
correlations
por: Di Vito, Anna, et al.
Publicado: (2017) -
The HFA‐PEFF score identifies ‘early‐HFpEF’ phenogroups associated with distinct biomarker profiles
por: Henkens, Michiel T.H.M., et al.
Publicado: (2022) -
Long-term outcomes in distinct phenogroups of patients with primary mitral regurgitation undergoing valve surgery
por: Kwak, Soongu, et al.
Publicado: (2023) -
A preclinical model for phenogroup 3 HFpEF
por: Yousefi, Keyvan, et al.
Publicado: (2019) -
Revascularization and Left Ventricular Dysfunction for ICD Eligibility
por: Romano, Letizia Rosa, et al.
Publicado: (2023)